This Article Full Text Full Text (PDF) All Versions of this Article: 35/1/196    most recent 01.STR.0000105390.20430.9Fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patel, A. Articles by Kalra, L. Search for Related Content PubMed PubMed Citation Articles by Patel, A. Articles by Kalra, L.

(Stroke. 2004;35:196.)
© 2004 American Heart Association, Inc.

Original Contributions

Alternative Strategies for Stroke Care

Cost-Effectiveness and Cost-Utility Analyses From a Prospective Randomized Controlled Trial

From the Centre for the Economics of Mental Health, Health Services Research Department, David Goldberg Centre, Institute of Psychiatry (A.P., M.K.); LSE Health and Social Care, London School of Economics and Political Science (M.K.); and Department of Medicine, Guy’s, King’s and St Thomas’ School of Medicine (I.P., A.E., L.K.), London, UK.

Reprint requests to Anita Patel, Box PO24, Centre for the Economics of Mental Health, Health Services Research Department, David Goldberg Centre, Institute of Psychiatry, De Crespigny Park, London SE5 8AF UK. E-mail a.patel{at}iop.kcl.ac.uk

Background and Purpose— Although stroke units reduce mortality and institutionalization, their comparative cost-effectiveness is unknown.

Methods— Healthcare, social services, and informal care costs were compared for 447 acute stroke patients randomly assigned to stroke unit, stroke team, or domiciliary stroke care. Prospective and retrospective methods were used to identify resource use over 12 months after stroke onset. Cost-effectiveness and cost-utility analyses were undertaken.

Results— Mean healthcare and social care costs over 12 months were £11 450 for stroke unit, £9527 for stroke team, and £6840 for domiciliary care. More than half the costs were for the initial episode of care. Institutionalization was a large proportion of follow-up costs. Inclusion of informal care increased costs considerably. When informal care was excluded, the incremental cost-effectiveness ratio per percentage point in deaths or institutionalizations avoided in the first year was £496 for the stroke unit over domiciliary care; incremental cost per quality-adjusted life year quality-adjusted life year gained was £64 097 between these 2 groups. The stroke team was dominated by domiciliary care.

Conclusions— Cost perspectives, especially those related to long-term and informal care, are important when stroke services are evaluated. Improved health outcomes in the stroke unit come at a higher cost.

Key Words: costs and cost analysis • randomized controlled trials • rehabilitation • stroke management

This article has been cited by other articles:

				A. I. Qureshi, M. F. K. Suri, A. Nasar, J. F. Kirmani, M. A. Ezzeddine, A. A. Divani, and W. H. Giles Changes in Cost and Outcome Among US Patients With Stroke Hospitalized in 1990 to 1991 and Those Hospitalized in 2000 to 2001 Stroke, July 1, 2007; 38(7): 2180 - 2184. [Abstract] [Full Text] [PDF]

				M. Moodie, D. Cadilhac, D. Pearce, C. Mihalopoulos, R. Carter, S. Davis, G. Donnan, and for the SCOPES Study Group Economic Evaluation of Australian Stroke Services: A Prospective, Multicenter Study Comparing Dedicated Stroke Units With Other Care Modalities Stroke, November 1, 2006; 37(11): 2790 - 2795. [Abstract] [Full Text] [PDF]

				M. Weinrich, M. Stuart, and T. Hoyer Rules for Rehabilitation: An Agenda for Research Neurorehabil Neural Repair, June 1, 2005; 19(2): 72 - 83. [Abstract] [PDF]

				D. B. Matchar and A. G. Rudd Health Policy and Outcomes Research 2004 Stroke, February 1, 2005; 36(2): 225 - 227. [Full Text] [PDF]

				D. Hanley and W. Hacke Critical Care and Emergency Medicine Neurology in Stroke Stroke, February 1, 2005; 36(2): 205 - 207. [Full Text] [PDF]

				G. Saposnik, F. Webster, C. O'Callaghan, and V. Hachinski Optimizing Discharge Planning: Clinical Predictors of Longer Stay After Recombinant Tissue Plasminogen Activator for Acute Stroke Stroke, January 1, 2005; 36(1): 147 - 150. [Abstract] [Full Text] [PDF]

				V. Aiyagari, A. Gujjar, A. R. Zazulia, and M. N. Diringer Hourly Blood Pressure Monitoring After Intravenous Tissue Plasminogen Activator for Ischemic Stroke: Does Everyone Need It? Stroke, October 1, 2004; 35(10): 2326 - 2330. [Abstract] [Full Text] [PDF]

				Other articles noted: 06 Feb 2004 to 16 Apr 2004 Evid. Based Nurs., July 1, 2004; 7(3): e3 - e3. [Full Text] [PDF]

				Other articles noted Evid. Based Med., May 1, 2004; 9(3): 95 - 96. [Full Text] [PDF]

				R. Holloway and A. W. Dick Editorial Comment--Stroke Cost-Effectiveness Research: Are Acceptability Curves Acceptable? Stroke, January 1, 2004; 35(1): 203 - 204. [Full Text] [PDF]